BTC Capital Management Inc. Has $254,000 Holdings in Novo Nordisk A/S (NVO)
BTC Capital Management Inc. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 42.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,446 shares of the company’s stock after selling 4,030 shares during the period. BTC Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $254,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Cozad Asset Management Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $341,000. Baldwin Investment Management LLC increased its position in shares of Novo Nordisk A/S by 63.5% during the second quarter. Baldwin Investment Management LLC now owns 13,136 shares of the company’s stock valued at $606,000 after acquiring an additional 5,100 shares in the last quarter. Banco de Sabadell S.A boosted its holdings in Novo Nordisk A/S by 3.5% in the second quarter. Banco de Sabadell S.A now owns 64,391 shares of the company’s stock worth $2,954,000 after purchasing an additional 2,200 shares during the last quarter. Natixis boosted its stake in shares of Novo Nordisk A/S by 62.0% during the 2nd quarter. Natixis now owns 6,959 shares of the company’s stock worth $321,000 after acquiring an additional 2,663 shares during the last quarter. Finally, Raymond James & Associates boosted its stake in shares of Novo Nordisk A/S by 5.2% during the 2nd quarter. Raymond James & Associates now owns 649,756 shares of the company’s stock worth $29,967,000 after acquiring an additional 32,152 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE NVO opened at $47.64 on Tuesday. The firm has a market capitalization of $119.66 billion, a price-to-earnings ratio of 20.36, a P/E/G ratio of 2.59 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $44.28 and a 52-week high of $58.37.
The business also recently declared a special dividend, which was paid on Tuesday, August 28th. Shareholders of record on Monday, August 20th were issued a $0.4669 dividend. The ex-dividend date of this dividend was Friday, August 17th. This represents a yield of 1.72%. Novo Nordisk A/S’s dividend payout ratio is currently 27.78%.
A number of research analysts recently weighed in on NVO shares. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, July 31st. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Monday, July 2nd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $64.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Read More: What is a Tariff?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.